Kangpu Biopharmaceuticals Receives NMPA Approval for KPG-818 Phase IIb Study in SLE
China-based Kangpu Biopharmaceuticals, Ltd announced that it has received approval from the National Medical Products...
April 2025
WuXi AppTec Reports 21.0% YOY Revenue Growth in Q1 2025
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) released its financial report...
Frontera Therapeutics’ Gene Therapy FT-017 Gains Clinical Trial Approvals for HCM
Sino-US biotech company Frontera Therapeutics, Inc. announced that its recombinant adeno-associated virus (rAAV) gene therapy...
Johnson & Johnson’s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer
US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort...
Regeneron’s Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the...
NMPA Issues New Quality Management Standards for Online Medical Device Sales
The National Medical Products Administration (NMPA) has released the “Announcement on Quality Management Standards for...
BeiGene’s Sonrotoclax NDA Accepted by NMPA for CLL/SLL Treatment
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...
NHSA Launches Intelligent Supervision Reform Pilot in Designated Medical Institutions
The National Healthcare Security Administration (NHSA) has released a notification to implement an intelligent supervision...
Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline
China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing...
OUR United Corporation Files for IPO in Hong Kong Stock Exchange
China-based OUR United Corporation, a leading provider of radiosurgical solutions, has filed for an initial...
Henlius Biotech’s HLX22 Receives Clinical Trial Approval in Germany for HER2-Positive Cancers
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received clinical trial approval...
GenScript to Acquire Additional Stake in Probio Cayman for USD 225.1 Million
GenScript Biotech Corporation (HKG: 1548) is set to acquire an additional 300 million Class A...
CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) reported its 2024 financial results, showing a 7.8%...
Innovent Biologics Posts 51.8% YOY Revenue Growth in 2024 Financial Report
China-based Innovent Biologics, Inc. (HKG: 1801) released its 2024 financial report, highlighting a robust growth...
Hengrui Pharmaceuticals Gains NMPA Clinical Clearance for Camrelizumab in Acral Melanoma
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...
Shouyao Holdings Gets Ethics Approval for SY-5933 Phase Ib/II Study in KRAS G12C Mutated Tumors
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced that it has received ethical approval...
Shouyao Holdings Unveils RMB787 Million Investment in Beijing BioPark R&D and GMP Facility
Shanghai-listed biopharmaceutical company Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) has announced plans to invest...
Biokin’s BL-B01D1 Secures NMPA Green-light for Two Phase II Clinical Trials in Gynecological Cancers
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...
Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply
German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China)...
CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors
Zhejiang-based Zhejiang Shimai Pharmaceutical Co.，Ltd (CentryMed)’s CMDE005, an anti-EGFR×CD3 enzyme-controlled bispecific antibody (BsAb) developed using...